Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations ba...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of Intestinal Diseases
2020-10-01
|
Series: | Intestinal Research |
Subjects: | |
Online Access: | http://www.irjournal.org/upload/pdf/ir-2019-09176.pdf |
id |
doaj-d476d9f9af8d4b87be95bb0d43044a87 |
---|---|
record_format |
Article |
spelling |
doaj-d476d9f9af8d4b87be95bb0d43044a872020-11-25T04:01:28ZengKorean Association for the Study of Intestinal DiseasesIntestinal Research1598-91002288-19562020-10-0118435537810.5217/ir.2019.09176856Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel diseaseAjit Sood0Vineet Ahuja1Vandana Midha2Saroj Kant Sinha3C. Ganesh Pai4Saurabh Kedia5Varun Mehta6Sawan Bopanna7Philip Abraham8Rupa Banerjee9Shobna Bhatia10Karmabir Chakravartty11Sunil Dadhich12Devendra Desai13Manisha Dwivedi14Bhabhadev Goswami15Kirandeep Kaur16Rajeev Khosla17Ajay Kumar18Ramit Mahajan19S. P. Misra20Kiran Peddi21Shivaram Prasad Singh22Arshdeep Singh23 Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India Department of Gastroenterology, Kasturba Medical College, Manipal, India Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India Fortis Hospital, New Delhi, India P. D. Hinduja Hospital and Medical Research Centre, Mumbai, India Asian Institute of Gastroenterology, Hyderabad, India Department of Gastroenterology, King Edward Memorial Hospital, Mumbai, India Department of Gastroenterology, AMRI Hospital, Kolkata, India Department of Gastroenterology, Dr. Sampurnanand Medical College, Jodhpur, India P. D. Hinduja Hospital and Medical Research Centre, Mumbai, India Department of Gastroenterology, Moti Lal Nehru Medical College, Allahabad, India Department of Gastroenterology, Gauhati Medical College, Guwahati, India Department of Pharmacology, Dayanand Medical College and Hospital, Ludhiana, India Max Super Speciality Hospital, Saket, New Delhi, India BLK Super Speciality Hospital, New Delhi, India Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India Department of Gastroenterology, Moti Lal Nehru Medical College, Allahabad, India Citizens Centre for Digestive Disorders, Hyderabad, India Department of Gastroenterology, Sriram Chandra Bhanj Medical College and Hospital, Cuttack, India Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, IndiaDespite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.http://www.irjournal.org/upload/pdf/ir-2019-09176.pdfinflammatory bowel disease5-aminosalicylic acidcrohn diseasecolitis, ulcerativemesalamine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ajit Sood Vineet Ahuja Vandana Midha Saroj Kant Sinha C. Ganesh Pai Saurabh Kedia Varun Mehta Sawan Bopanna Philip Abraham Rupa Banerjee Shobna Bhatia Karmabir Chakravartty Sunil Dadhich Devendra Desai Manisha Dwivedi Bhabhadev Goswami Kirandeep Kaur Rajeev Khosla Ajay Kumar Ramit Mahajan S. P. Misra Kiran Peddi Shivaram Prasad Singh Arshdeep Singh |
spellingShingle |
Ajit Sood Vineet Ahuja Vandana Midha Saroj Kant Sinha C. Ganesh Pai Saurabh Kedia Varun Mehta Sawan Bopanna Philip Abraham Rupa Banerjee Shobna Bhatia Karmabir Chakravartty Sunil Dadhich Devendra Desai Manisha Dwivedi Bhabhadev Goswami Kirandeep Kaur Rajeev Khosla Ajay Kumar Ramit Mahajan S. P. Misra Kiran Peddi Shivaram Prasad Singh Arshdeep Singh Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease Intestinal Research inflammatory bowel disease 5-aminosalicylic acid crohn disease colitis, ulcerative mesalamine |
author_facet |
Ajit Sood Vineet Ahuja Vandana Midha Saroj Kant Sinha C. Ganesh Pai Saurabh Kedia Varun Mehta Sawan Bopanna Philip Abraham Rupa Banerjee Shobna Bhatia Karmabir Chakravartty Sunil Dadhich Devendra Desai Manisha Dwivedi Bhabhadev Goswami Kirandeep Kaur Rajeev Khosla Ajay Kumar Ramit Mahajan S. P. Misra Kiran Peddi Shivaram Prasad Singh Arshdeep Singh |
author_sort |
Ajit Sood |
title |
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease |
title_short |
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease |
title_full |
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease |
title_fullStr |
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease |
title_full_unstemmed |
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease |
title_sort |
colitis and crohn’s foundation (india) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease |
publisher |
Korean Association for the Study of Intestinal Diseases |
series |
Intestinal Research |
issn |
1598-9100 2288-1956 |
publishDate |
2020-10-01 |
description |
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD. |
topic |
inflammatory bowel disease 5-aminosalicylic acid crohn disease colitis, ulcerative mesalamine |
url |
http://www.irjournal.org/upload/pdf/ir-2019-09176.pdf |
work_keys_str_mv |
AT ajitsood colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT vineetahuja colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT vandanamidha colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT sarojkantsinha colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT cganeshpai colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT saurabhkedia colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT varunmehta colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT sawanbopanna colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT philipabraham colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT rupabanerjee colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT shobnabhatia colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT karmabirchakravartty colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT sunildadhich colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT devendradesai colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT manishadwivedi colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT bhabhadevgoswami colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT kirandeepkaur colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT rajeevkhosla colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT ajaykumar colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT ramitmahajan colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT spmisra colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT kiranpeddi colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT shivaramprasadsingh colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease AT arshdeepsingh colitisandcrohnsfoundationindiaconsensusstatementsonuseof5aminosalicylicacidininflammatoryboweldisease |
_version_ |
1724446847536201728 |